Vertex Pharm reports data from Phase 2 Study of an INCIVEK combination regimen showed 74% of people co-infected with hepatitis C and HIV had undetectable hepatitis C virus 12 weeks after treatment ended (SVR12) (VRTX) 39.91 -0.52 : Co announced interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with genotype 1 hepatitis C virus and human immunodeficiency virus (HIV). Data showed 74 percent (28/38) of patients who were treated with INCIVEK combination therapy had undetectable hepatitis C virus (HCV RNA) 12 weeks after the end of all study treatment (SVR12) compared to 45 percent (10/22) who were treated with pegylated-interferon and ribavirin alone. INCIVEK was well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens.
